Related coverage linked through entity extraction aliases.
Jul 14, 2026
Qiagen launched the QIA Agent AI assistant for lab workflows and expanded its NVIDIA collaboration in bioinformatics. Valuation narratives peg the stock as undervalued, with fair value estimates around $53.53–$54.61, though momentum and funding risks remain.
Mar 25, 2026
The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.
Feb 24, 2026
The global oncology precision medicine market is projected to grow from $190.50 billion in 2026 to $366.53 billion by 2033 at a 9.8% CAGR, while the cancer biomarker testing market is expected to reach $96.53 billion by 2033 at a 12.6% CAGR.
